Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
SC TO-C
Information about tender offer
8 Apr 24
PRE 14A
Preliminary proxy
8 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
29 Feb 24
8-K
Other Events
20 Feb 24
8-K
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Dec 23
8-K
Departure of Directors or Certain Officers
8 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2 Nov 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
S-8
Registration of securities for employees
2 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
2 Aug 23
8-K
Departure of Directors or Certain Officers
25 May 23
EFFECT
Notice of effectiveness
8 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
4 May 23
CORRESP
Correspondence with SEC
3 May 23
ARS
2022 FY
Annual report to shareholders
11 Apr 23
DEFA14A
Additional proxy soliciting materials
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
PRE 14A
Preliminary proxy
31 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
UPLOAD
Letter from SEC
21 Feb 23
S-3
Shelf registration
17 Feb 23
S-8
Registration of securities for employees
17 Feb 23
10-K
2022 FY
Annual report
17 Feb 23
8-K
Departure of Directors or Certain Officers
15 Feb 23
8-K
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
15 Feb 23
8-K
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
9 Jan 23
EFFECT
Notice of effectiveness
4 Jan 23
CORRESP
Correspondence with SEC
29 Dec 22
UPLOAD
Letter from SEC
28 Dec 22
S-3
Shelf registration
23 Dec 22
8-K
Other Events
13 Dec 22
D
$165.00 mm in equity / options / securities to be acquired, sold $165.00 mm, 33 investors
8 Dec 22
Latest ownership filings
4
Reshma Rangwala
23 Apr 24
4
Richard A. Paulson
5 Apr 24
4
Richard A. Paulson
6 Mar 24
4
Reshma Rangwala
4 Mar 24
4
Stuart Poulton
4 Mar 24
4
Michael Mason
4 Mar 24
4
Michael Mano
4 Mar 24
4
Sohanya Roshan Cheng
4 Mar 24
4
Richard A. Paulson
4 Mar 24
4
Reshma Rangwala
29 Feb 24
4
Stuart Poulton
29 Feb 24
4
Michael Mason
29 Feb 24
4
Michael Mano
29 Feb 24
4
Sohanya Roshan Cheng
29 Feb 24
4
Richard A. Paulson
29 Feb 24
4
Stuart Poulton
20 Feb 24
SC 13G/A
Palo Alto Investors LP
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
4
Michael Mason
8 Feb 24
4
Richard A. Paulson
8 Feb 24
4
Sohanya Roshan Cheng
25 Jan 24
4
Reshma Rangwala
25 Jan 24
4
Stuart Poulton
25 Jan 24
4
Michael Mano
25 Jan 24
4
Michael Mason
25 Jan 24
4
Richard A. Paulson
25 Jan 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
4
Richard A. Paulson
8 Jan 24
4
Richard A. Paulson
5 Dec 23
4
Richard A. Paulson
7 Nov 23
4
Richard A. Paulson
5 Oct 23
4
GAREN G BOHLIN
12 Sep 23
4
Richard A. Paulson
6 Sep 23
4
Michael Mason
5 Sep 23
4
Michael Mano
5 Sep 23
4
Sohanya Roshan Cheng
5 Sep 23
4
Zhen Su
1 Sep 23